Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases
Authors:
Open Access
- 28 January 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (3) , 1961-1978
Abstract
Metabolic diseases are increasing at staggering rates globally. The peroxisome proliferator-activated receptors (PPARα/γ/δ) are fatty acid sensors that help mitigate imbalances between energy uptake and utilization. Herein, we report compounds derived from phenolic lipids present in cashew nut shell liquid (CNSL), an abundant waste byproduct, in an effort to create effective, accessible, and sustainable drugs. Derivatives of anacardic acid and cardanol were tested for PPAR activity in HEK293 cell co-transfection assays, primary hepatocytes, and 3T3-L1 adipocytes. In vivo studies using PPAR-expressing zebrafish embryos identified CNSL derivatives with varying tissue-specific activities. LDT409 (23) is an analogue of cardanol with partial agonist activity for PPARα and PPARγ. Pharmacokinetic profiling showed that 23 is orally bioavailable with a half-life of 4 h in mice. CNSL derivatives represent a sustainable source of selective PPAR modulators with balanced intermediate affinities (EC50 ∼ 100 nM to 10 μM) that provide distinct and favorable gene activation profiles for the treatment of diabetes and obesity.Keywords
Funding Information
- Government of Canada
- Israel Science Foundation
- International Development Research Centre (109155-001)
- Minist??rio da Ci??ncia, Tecnologia e Inova????o (310509/2011-4, 3308486/2020-0, 490203/2012-4)
- Azrieli Foundation
- Government of Canada (RGPIN 03666-14, RGPIN-2020-07212)
- Coordena????o de Aperfei??oamento de Pessoal de N??vel Superior
- Ontario Institute for Cancer Research
This publication has 50 references indexed in Scilit:
- LXRβ is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in miceJournal of Clinical Investigation, 2011
- Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5Nature, 2010
- PPARα: an emerging therapeutic target in diabetic microvascular damageNature Reviews Endocrinology, 2010
- Metabolic Syndrome and Incident DiabetesDiabetes Care, 2008
- Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-κB–regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-κBα kinase, leading to potentiation of apoptosisBlood, 2008
- Mechanisms linking obesity to insulin resistance and type 2 diabetesNature, 2006
- International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated ReceptorsPharmacological Reviews, 2006
- Principles for modulation of the nuclear receptor superfamilyNature Reviews Drug Discovery, 2004
- Regulation of Muscle Fiber Type and Running Endurance by PPARδPLOS Biology, 2004
- Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factorCell, 1994